We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
8
3 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
3
37.5%
Completed
2
25.0%
Recruiting
Terminated
1
12.5%
No approval data available
- LeMaitre Vascular posted Q2 2026 sales of $70.4 million, a 10% organic increase, with Artegraft sales surging 34% to account for 21% of total revenue. - Gross margin expanded 210 basis points to 72.1%, while operating income rose 26% to a record $20.4 million, representing a 29% operating margin. - The company raised its 2026 Artegraft sales forecast to $11 million and now has regulatory approvals in 56 countries, with recent additions including Vietnam, Morocco, and Turkey. - Full-year 2026 guidance projects $276.3 million in revenue with 11% organic growth and EPS of $2.89, up 21% on an adjusted basis.
